Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, is proud to announce its ...

Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $32.15 which represents a slight increase of $1.81 or 5.97% from the prior close of $30.34. The stock opened at ...

Hims & Hers Health Inc. shares surged 24% to close at fresh record after Hunterbrook Media said the company is poised to be a ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s stock price gapped up prior to trading on Monday after Canaccord Genuity Group raised their price target on the stock from $28.00 to $38.00.

Canaccord raised the firm’s price target on Hims & Hers to $38 from $28 and keeps a Buy rating on the shares. The stock rallied 70% in ...

Amazon acquired primary care provider One Medical for $3.9 billion in 2022, and fills prescriptions through Amazon One ...

Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and ...

Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Find out what positions HIMS as a key ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.